Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | DNTT | P04053 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11419180 | 1.00 | AKR1C4 (0.38) | AKR1C4AKR1C3AKR1C2DNTTTRPA1 | |
| SCHEMBL11419181 | 1.00 | AKR1C4 (0.38) | AKR1C4AKR1C3AKR1C2DNTTTRPA1 | |
| SCHEMBL30127903 | 0.84 | AKR1C4 (0.50) | AKR1C4AKR1C3AKR1C2DNTTTRPA1 | |
| SCHEMBL19720143 | 0.76 | DNTT (0.57) | DNTTTRPA1POLBSMN1; SMN2PTGER4 | |
| SCHEMBL19736431 | 0.76 | DNTT (0.41) | DNTTALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL10629072 | 0.74 | AKR1C4 (0.40) | AKR1C4AKR1C3AKR1C2TRPA1MEN1 | |
| SCHEMBL28744721 | 0.74 | AKR1C4 (0.40) | AKR1C4AKR1C3AKR1C2TRPA1MEN1 | |
| SCHEMBL10631187 | 0.74 | AKR1C4 (0.40) | AKR1C4AKR1C3AKR1C2TRPA1MEN1 | |
| SCHEMBL2948236 | 0.74 | PTGER4 (0.48) | DNTTTRPA1MEN1ALDH1A1LMNA | |
| SCHEMBL2948238 | 0.74 | PTGER4 (0.48) | DNTTTRPA1MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284252-B2 | Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders | SEPAL PHARMA LTD. (IL) | 2016-03-15 | — | — | US | disclosed |
| US-20150080430-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD. (IL) | 2015-03-19 | — | — | US | disclosed |
| US-20150080430-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD. (IL) | 2015-03-19 | — | — | US | disclosed |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
| WO-2010143180-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
| US-20100003346-A1 | COMBINATION METHODS OF TREATING CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-01-07 | — | — | US | disclosed |
| US-20100003346-A1 | COMBINATION METHODS OF TREATING CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-01-07 | — | — | US | disclosed |
| WO-2009019693-A2 | ANALGESIC EFFECT OF JASMONATE DERIVATIVES | SEPAL PHARMA SA (FR) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008007367-A1 | COMBINATION METHODS OF TREATING CANCER | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080430-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | DGKK, KRT18, DGKG | AKR1C4 488/4885AKR1C3 489/4885AKR1C2 299/4885 |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | MYC, KRT18, DGKK | AKR1C4 390/4885AKR1C3 401/4885AKR1C2 259/4885 |
| US-20100003346-A1 | COMBINATION METHODS OF TREATING CANCER | G6PD, PGD, PDK2 | AKR1C4 460/4885AKR1C3 560/4885AKR1C2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.